salarius-logo-rgb-72dpi.jpg
Salarius Announces Proposed Public Offering of Common Stock
29 juil. 2020 16h15 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical Trial
29 juil. 2020 16h05 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Announces Move to New Corporate Offices at Texas Medical Center
28 juil. 2020 08h00 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Names Nadeem Mirza, M.D., M.P.H., as Senior Vice President Clinical Development
23 juil. 2020 08h00 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, July 23, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Invited to Present Seclidemstat Research at Meeting of the Pediatric Oncology Subcommittee of the Food and Drug Administration’s Oncologic Drugs Advisory Committee
02 juin 2020 09h00 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, June 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program
27 mai 2020 08h00 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results
14 mai 2020 16h05 HE | Salarius Pharmaceuticals, Inc.
Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020 Conference Call and Live Audio Webcast Scheduled for Today, May 14, 2020, at...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program
14 mai 2020 08h00 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results
07 mai 2020 16h05 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, May 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting
29 avr. 2020 07h30 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, April 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...